Elecsys® SCC

An important part of Roche’s portfolio in tumor markers for managing patients with squamous cell cancers

Elecsys SCC

An important part of Roche’s portfolio in tumor markers for managing patients with squamous cell cancers

The SCC assay is used as an aid in the management of patients with squamous cell carcinoma in conjunction with other methods that align to the standard ­clinical management guidelines.

SCCA levels can be elevated in squamous cell cancers and it has been ­reported that more advanced cancer stages are associated with higher SCCA levels ­especially in lung and cervical cancer.1,2 It was reported that measurement of the ­antigen, in serial determinations, aids in the assessment of disease recurrence, residual disease following treatment, and response to therapy.3,4

SCC antigen in different types of squamous cell cancers:

  • SCCA has been reported as a biomarker for a non-small cell lung cancer (NSCLC), mainly of the squamous cell carcinoma type. SCC in lung is closely correlated with a history of tobacco ­smoking, more than other types of lung cancer.5 Based on literature, SCCA elevated serum levels were found to be indicative of NSCLC if renal failure and dermatological diseases were excluded.6
  • The most common histology in cervical cancer is SCC, with SCCA being the biomarker of choice for this histology. Serum levels of SCCA have been found to correlate with tumor stage, tumor size and ­residual tumor after treatment, recurrent or progressive disease, and survival in ­patients with squamous cell cervical ­cancer.7,8




  • Measuring SCC antigen in lung cancer patients gives a clearer picture on the patients status
  • SCC antigen as biomarker for cervical cancer is another tool in patient management together with other markers for gynecological malignancies (i.e. CA 125, HE4, CA 15-3, HPV, CINtec® PLUS Cytology)
  • High assay precision for accurate and sustainable results for patient monitoring
  • One blood sample for all lung cancer ­biomarkers for time and cost efficiency
  • High reagent on-board stability
  • Short turn around time for fast results



Product specifications

  • Assay time

    18 min

  • Sample material

    Serum, plasma

  • Sample volume

    15 μL

  • Measuring range

    0.1– 70 ng/mL

  • LoQ

    0.24 ng/mL

  • Precision

    5 % CV

  • Standardization

    Abbott Architect

  • Detection of SCC antigen 1 and 2

  1. Einarsson, R. (2005). Squamous Cell Carcinoma Antigen (SCCA) Isomers- Markers for squamous cell carcinoma. Adv. Clin. Exp. Med.; 14: 643-648. 
  2. Henry, R.J., Dodd, J.K., Tyler, J.P., and Houghton, C.R. (1987). SCC Tumor Marker and Its Relationship to Clinical Stage in Squamous Cervical Cancer. Aust. NZl. Obstet. Gynaecol.; 27: 338-340. 
  3. Kenter, G., Bonfrer, J.M.G. and Heintz, A.P.M. (1987). Pretreatment Tumor-Antigen TA-4 in Serum of Patients With Squamous Cell Carcinoma of the Uterine Cervix. Br. J. Cancer; 56: 157-158. 
  4. Barak, V., Holdenrieder, S., Nisman, B., et al. (2009/2010). Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomarkers; 6: 191-196. 
  5. Kenfield, S.A., Wei, E.K., Stampfer, M.J., Rosner, B.A., Colditz, G.A. (2008). Comparison of aspects of smoking among the four histological types of lung cancer. Tobacco Control; 17: 198–204. 
  6. Molina, R., Auge, J.A., Escudero, J.M., et al. (2008). Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.4 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE. Tumor. Biol.; 29: 371-380. 
  7. Lozza, L., Merola, M., Fontanelli, R., et al. (1997). Cancer of the uterine cervix: clinical value of squamous cell carcinoma antigen (SCC) measurements. Anticancer Research; 17: 525-530. 
  8. Kato, H. et al. (1983). Prognostic significance of the tumor antigen T4-A in squamous cell carcinoma of the uterine cervix. Am. J. Obstet. Gynecol.; 145: 350-354.